Market Signal Briefing

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p

SummaryI am upgrading Chipotle to a “buy” with a $52 price target per share, implying 26% upside from current levels.Chipotle’s Q2 FY25 results were disappointing, but management’s focus on technology, menu innovation, and loyalty programs is expected to drive growth from Q3 onward.Plus, Chipotle has been improving its profitability driven by cost controls and menu pricing, with revenue and earnings growth expected to accelerate through FY27.I believe that there is room for multiple expansions, as acceleration in both its top and bottom lines from Q3 onwards could lead to a potential stock rerating.sanfel/iStock Editorial via Getty Images

Introduction & Investment Thesis When I last wrote about Chipotle (CMG), I reiterated my "hold" rating, as I believed the pain was not over yet. In the post, I discussed that the company would face tougher comps for

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CMG over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- MAGACOIN FINANCE, an Ethereum-based cryptocurrency project, today announced it has raised over $15.5 million in its ongoing presale with more than 14 000 global investors.

The milestone arrives amid growing Bitcoin ETF anticipation, which is driving renewed interest in Ethereum-built altcoins showing measurable traction.

Presale Highlights

Funds raised: $15.5 million +
Investors: 14 000 + participants
Allocation sold: ≈ 80 % complete
Launch price: $0.007 per token The project’s stage-based model raises token prices incrementally as supply shrinks, creating a built-in scarcity mechanism for early participants.

Bitcoin ETF Momentum and Altcoin Shift

With market focus centered on pending Bitcoin ETF developments, analysts report a spillover of capital toward lower-cap Ethereum projects like MAGACOIN FINANCE. The project’s $15.5 M achievement places it among the cycle’s most funded early-stage entries.

Why Investors Are Watching

Measured funding milestone of $15.5 M.
Large and growing global community.
Ethereum-based architecture aligned with institutional trends

Conclusion

As ETF buzz builds around Bitcoin and flows extend to altcoins, MAGACOIN FINANCE’s fundraising progress highlights the market’s renewed appetite for Ethereum-based projects with clear tokenomics and presale momentum.

About MAGACOIN FINANCE

MAGACOIN FINANCE is an Ethereum-based cryptocurrency project combining cultural relevance with scalable blockchain utility. With over $15.5 million raised and a rapidly growing community, it aims to be a leading altcoin entrant of 2025.

Learn more:

Website: https://magacoinfinance.com
Access: https://magacoinfinance.com/access
Twitter/X: https://x.com/magacoinfinance
Telegram: https://t.me/magacoinfinance

Contact Details

PR Specialist: Rebecca Miles
Email: [email protected]

Disclaimer: This content is provided by MAGACOIN FINANCE. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector--including cryptocurrency, NFTs, and mining--complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.

Legal Disclaimer: This media platform provides the content of this article on an "as-is" basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/28c20655-503f-4a9b-87f7-265bdbb32da2

https://www.globenewswire.com/NewsRoom/AttachmentNg/01040c99-688e-41ce-ba87-98a380eb6a2b

https://www.globenewswire.com/NewsRoom/AttachmentNg/4a13f696-ad93-40b5-a903-f6ec8c8ceb54

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

October 05, 2025 09:00 ET

 | Source:

Spyre Therapeutics, Inc.

WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced scientific presentations at the UEGW Congress.

“We are excited to share follow-up data out to six months from our Phase 1 study of SPY002, our potential best-in-class anti-TL1A agent in development for IBD. The data continue to show SPY002 is well tolerated, has a differentiated PK profile supporting quarterly or twice-yearly dosing, and suppresses free TL1A through 24 weeks,” said Josh Friedman, M.D., Ph.D., SVP of Clinical Development at Spyre. “Additionally, we are pleased to share new preclinical data demonstrating that each of our combination programs (α4β7 + TL1A, α4β7 + IL-23, and TL1A + IL-23) exhibit superior efficacy relative to constituent monotherapies in rodent TNBS-induced colitis models, providing additional validation for our ongoing SKYLINE-UC Phase 2 study.”

The poster will be available for viewing during the UEGW Congress, and details are as follows:

Title: Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggests a Potential for Q3M or Q6M Maintenance Dosing for Inflammatory Bowel Disease
Authors: Y. Vugmeyster, S. Sloan, JD Lu, K. Hew, P. Patel, C. Sheldon, D. Nguyen, R. McLean, M. Huyghe, B. Connolly, B. Wang, M. Kennedy, M. Rose, E. Svejnoha, J. Friedman

Title: Combined Inhibition of Integrin β7 and TL1A, Integrin β7 and IL-23, or TL1A and IL-23 Are Superior to Their Constituent Monotherapies in Mouse TNBS-Induced Colitis
Authors: M. Siegel, J. Friedman, E. Lewis, D. Giles, A. Spencer

Full session details can be accessed via the UEGW program.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com. 

Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Spyre's management team's expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, Spyre’s ability to achieve the expected benefits or opportunities with respect to its pipeline of product candidates such as the potential efficacy, tolerability, convenience, commercial viability, dosing regimen and safety profile of SPY002 in humans, including the potential for a quarterly or twice yearly dosing profile; the potential for SPY002 to become a best-in-class therapy for IBD; the potential consistency of the SPY002 Phase 2 trial final data readouts with interim Phase 1 results; and the potential therapeutic benefits of Spyre’s product candidates as monotherapies or in combinations and their extended half-life, including the expected duration of half-life in comparison to competitor products and the potential potency, efficacy and convenience compared to today’s standard of care. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "aim," "strategy," "target," "seek," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "predict," "project," "should," "will," "would," and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Spyre will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates, including our plans for and timing of cohort initiation for combination therapy arms for the ongoing SKYLINE-UC Phase 2 platform trial across different jurisdictions; the potential for final data not being consistent with or different than the interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described under the heading "Risk Factors," "Risk Factor Summary" and "Note about Forward-Looking Statements" in Spyre's most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has filed or will file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Spyre from time to time. Should one or more of these risks or uncertainties materialize, or should any of Spyre's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.

For Investors:     
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
[email protected] 

For Media:     
Josie Butler, 1AB
[email protected] 

, /PRNewswire/ -- Berger Montague PC, national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc.  (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period").

Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE .

LifeMD, headquartered in New York, New York, is a telehealth provider offering direct-to-patient virtual care and pharmacy services.

According to the suit, LifeMD issued materially false and/or misleading statements regarding its business and financial outlook. Specifically, the Company is accused of overstating its competitive position and raising its 2025 guidance without adequately accounting for escalating customer acquisition costs—particularly within its RexMD segment and for obesity-related drugs like Wegovy and Zepbound.

When the true facts were revealed, LifeMD shares fell 44%, or $5.31 per share, in a single trading session.

If you are a LifeMD investor and would like to learn more about this action, CLICK HERE  or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague
Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:

Andrew Abramowitz
Senior Counsel
Berger Montague
(215) 875-3015
[email protected]

Caitlin Adorni
Director of Portfolio and Institutional Client Monitoring Services
Berger Montague
(267) 764-4865
[email protected] 

SOURCE Berger Montague

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Pfizer's stock has been struggling for multiple years, and even a low valuation hasn't made it an enticing option for many investors.

Pfizer (PFE 1.03%) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.

It has developed many medicines over the years; most recently, it has been known for developing its highly successful COVID vaccine Comirnaty. Growth and innovation have enabled the company to become a household name and a leader in healthcare.

Investors, however, have been having doubts about the business and its ability to grow in the future. In the past three years, the stock has produced negative returns. Since 2022, It has lost more than half its value. Can the stock break its downward streak, and finish this year in positive territory?

Image source: Getty Images.

A recent deal with the White House gives investors hope
For a while, it looked like Pfizer's stock was destined for another year in the red. The U.S. government has been targeting pharma companies with tariffs this year, and tougher vaccine policies have also been weighing on the company's valuation.

But on Sept. 30, Pfizer reached a deal with President Donald Trump that will give it a grace period of three years before tariffs would be applied to its imported pharmaceutical products. The company is voluntarily lowering the price of drugs for Medicaid and will sell some drugs on TrumpRx, a new government-run direct-to-consumer website for pharmaceuticals. In addition, the company also pledged to invest $70 billion on research and manufacturing in the U.S. over the coming years.

This appeared to alleviate at least some concerns for investors because shares of Pfizer jumped on the recent news. On Oct. 1, it closed above $27 for the first time since January. The stock is now in positive territory for 2025, with year-to-date gains around 3%. It's not a huge return, but it is an indication that investors are feeling a bit more bullish about the healthcare stock again and that it might be able to finish the year in the green.

Pfizer still faces a lot of questions
Although the stock has been rallying recently, it's not out of the woods by any means. COVID sales are diminishing for Pfizer, and the company is facing patent cliffs on multiple key drugs.

CEO Albert Bourla has previously said the company could stand to lose between $16 billion and $18 billion in revenue between 2025 and 2030 as it loses patent protection on some of its drugs. However, he's also planning to add $25 billion in new revenue by the end of the decade through acquisitions and research and development.

Its acquisition of oncology company Seagen could generate up to $10 billion in sales by 2030 alone. It was also expecting that its mRNA vaccine portfolio might bring in a similar amount, but that is questionable now that the U.S. government appears to be rethinking vaccine recommendations.

The business may end up looking a whole lot different over the next five-plus years. While its fundamentals still look good (it generated nearly $11 billion in profits over the trailing 12 months), investors are hesitant about whether or not they can trust this struggling stock, especially amid such uncertain times in the healthcare sector.

Why Pfizer may be worth taking a chance on
There's definitely risk with investing in Pfizer as it's taking on multiple acquisitions and facing patent cliffs, and there are plenty of question marks around its vaccine sales. However, with a beaten-down valuation, a price-to-earnings multiple of less than 13, and a price-to-earnings-growth ratio right around 1 (based on analyst projections), it's a low-priced stock that comes with a good margin of safety.

Pfizer has been working on expanding its pipeline and giving itself more opportunities to grow in the long run. Although not all of its efforts might pay off, even if some do, there could be plenty of catalysts in the future to send the stock higher.

Whether it breaks its streak of declines this year is irrelevant because investing in a quality company at a cheap price could ensure your investment ends up in the green over the long haul, and that's why Pfizer looks like a solid buy, regardless of what happens in the short term.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

SummaryToyota remains the world's largest automaker, boasting strong global sales and industry-leading profitability despite recent tariff headwinds.TM's strategic decision to limit price hikes, leverage U.S. manufacturing, and absorb tariff costs is fueling sales growth while competitors raise prices.With a forward P/E of 10.77 and robust revenue growth, TM is undervalued and offers a low-risk, long-term opportunity.Toyota's reliable brand, operational excellence, and prudent strategy make TM a compelling buy-and-hold stock, well-positioned to outperform in a competitive industry.Zigmunds Dizgalvis/iStock Editorial via Getty Images

Toyota (NYSE:TM)(OTCPK:TOYOF) needs no introduction. The Japanese auto giant has been the largest car manufacturer in the world by volume for several years running. It sold more than 10 million

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

The share price of American technology giant Oracle (NASDAQ: ORCL) is looking to extend its recent momentum, with technical indicators pointing toward a potential move to the $1,000 level.

Notably, Oracle stock ended the last session trading at $286, having gained about 125% in the past six months, a rally largely driven by the company’s expanding role in the artificial intelligence sector.

ORCL one-month stock price chart. Source: Finbold
Now, analysis by charting platform TrendSpider suggests Oracle may be primed for another major rally toward $1,000, if historical patterns repeat. 

Orcale stock price analysis chart. Source: TrendSpider
The October 5 post on X used a monthly logarithmic chart comparing Oracle’s current price action to its 2000 Dot-com surge, when the stock soared before a sharp correction and long consolidation.

In the current setup, the highlighted 2025 zone mirrors the same sharp upward trajectory that preceded Oracle’s last parabolic move. If the historical fractal plays out proportionally, the projection suggests Oracle could extend its multi-year uptrend toward the $1,000 and $1,031 range.

Oracle stock fundamentals 
While the analysis doesn’t guarantee future gains, Oracle’s strong fundamentals could sustain the rally. For instance, the company’s latest quarterly report showed a 359% year-over-year surge in remaining performance obligations to about $455 billion, reflecting a robust cloud and AI service backlog and strong revenue visibility.

Another key catalyst is a new cloud deal expected to generate roughly $30 billion in annual revenue, reportedly linked to AI infrastructure clients such as OpenAI.

 Oracle’s participation in the Stargate project,  a multibillion-dollar AI data center initiative co-developed with OpenAI and SoftBank,  further strengthens its enterprise AI positioning.

To support this growth, Oracle has raised its capital expenditure target to $35 billion, plans to open 37 new data centers, and issued $18 billion in bonds, aligning with Big Tech’s accelerated AI buildout trend.

Leadership changes have also boosted investor confidence. To this end, ORCL shares surged in reaction in September 2025, when Clay Magouyrk and Mike Sicilia were appointed co-CEOs, replacing Safra Catz. 

Featured image via Shutterstock

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryUnited Airlines is poised to outperform, driven by industry-leading capacity growth and strong premium and international demand.UAL's Q3 results should reflect robust revenue growth, resilient premium cabin performance, and expanding high-margin loyalty revenues, offsetting basic economy softness.Despite superior growth, margins, and balance sheet, UAL trades at a discount to peers, presenting a 35% upside to a $129 price target.I reiterate a “buy” rating on UAL, citing strong fundamentals and growth, while acknowledging risks from economic cycles, fuel, and labor costs. Laser1987/iStock Editorial via Getty Images

Introduction United Airlines (NASDAQ:UAL) shareholders have had a turbulent year. After a sharp descent over fears of tariff impacts on the U.S. economy, the shares quickly regained altitude as passenger demand remained strong.

In my previous coverage, I argued that

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox.

Concrete manufacturing, and especially cement production, accounts for 8% of global greenhouse gas emissions, according to the World Economic Forum. That's about the same as the world's third- or fourth-largest country's annual output. 

And that's why large users of concrete, some of the biggest names in real estate, are joining forces to support low-carbon concrete. Amazon, Meta and Prologis are joining other organizations in founding the Sustainable Concrete Buyers Alliance, or SCoBA. The group is led by nonprofits RMI, previously known as the Rocky Mountain Institute, and the Center for Green Market Activation.

"We're looking to channel their investments into real off-take agreements that will then enable low-carbon cement and concrete producers to invest in decarbonization projects and ultimately accelerate the market," said Ben Skinner, a manager on the cement and concrete team at RMI.

The idea is to use their collective purchasing power for low-carbon concrete and thereby financially support sustainable concrete production. It could also help to finance capital-intensive decarbonization projects, which improves market conditions for those low-carbon concrete producers to grow their technologies and their businesses.

"Low-carbon cement and concrete are essential to decarbonizing the built environment, and this alliance will help bring next-generation solutions to scale for the benefit of our customers," said Keara Fanning, director of net zero and sustainability at Prologis, the world's largest warehouse REIT, or real estate investment trust.

The problem the organizations are trying to tackle is one of scale. Large cement suppliers who do have net zero commitments operate massive plants, and so making the retrofits needed to decarbonize their product is extremely expensive. They need to see legitimate demand in the marketplace before they're willing to make the investment. 

Get Property Play directly to your inboxCNBC's Property Play with Diana Olick covers new and evolving opportunities for the real estate investor, delivered weekly to your inbox.

Subscribe here to get access today.

On the other side of the coin, cement buyers who may want to reduce their emissions are having a hard time finding low-carbon cement because the suppliers don't think there is enough demand for it. SCoBA will connect its members with leading producers of clean cement.

"What we're doing is bringing together all of those buyers, collectively. They have sufficient buying power to actually move the market, show the suppliers, enable the suppliers to actually invest in these decarbonization technologies," said Skinner.

They will do this through so-called book-and-claim, which is a more innovative demand-side mechanism that will help expand the market. It's the same system used in the renewable energy market, where consumers purchase a certificate for the environmental benefits of a sustainable product, but they don't actually physically get that product itself. 

"It doesn't make logical sense for an ambitious buyer in New York to ship cement that is low-carbon all the way from California for their project. So rather, what we're enabling would be a transaction in which they are buying an environmental attribute certificate that gives them the rights to that low-carbon product, but the physical product is actually being sourced locally," Skinner explained.

The goal is to break down that geographical boundary seen in the cement and concrete industry, which has a very long and complex supply chain. It will also help innovators in the space, such as California-based startup Brimstone, which was invited to participate and provide data for the alliance. 

"It's a huge win when some of the biggest companies in the world join together to build a market for sustainable concrete," said Cody Finke, CEO of Brimstone. "It gives companies like Brimstone a faster path to market — putting our cement into buildings, data centers and infrastructure sooner."

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryHormel Foods trades near its 52-week low, offering a compelling entry for value investors with a 4.7% dividend yield.HRL demonstrates solid organic growth in retail, foodservice, and international segments, driven by strong brands and ongoing innovation.Despite margin pressure from higher input costs, HRL's transformation and modernization initiatives support long-term growth and operational efficiency.I rate HRL stock as a 'buy' for its dividend strength, earnings growth potential, and attractive valuation, targeting mid-teens total returns.Looking for a portfolio of ideas like this one? Members of iREIT®+HOYA Capital get exclusive access to our subscriber-only portfolios. Learn More » CatLane/E+ via Getty Images

I’ve largely stayed on the sidelines over the past year on food stocks, as headwinds from inflation and the ‘MAHA’ movement have pressured prices in the sector. However, I find the valuations now to be compelling, providing an attractive entry point

Analyst’s Disclosure:I/we have a beneficial long position in the shares of HRL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am not an investment advisor. This article is for informational purposes and does not constitute as financial advice. Readers are encouraged and expected to perform due diligence and draw their own conclusions prior to making any investment decisions.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

It’s been a tough year for Starbucks NASDAQ: SBUX. The king of coffee retail chains has seen its stock slide more than 25% from its year-to-date (YTD) high on Feb. 23, and when it reported Q3 earnings on July 29, it missed analysts’ estimates by nearly 28%.  

Starbucks Today

$86.42 -0.30 (-0.35%)

As of 10/3/2025 04:00 PM Eastern

52-Week Range$75.50▼

$117.46Dividend Yield2.82%

P/E Ratio37.25

Price Target$104.00

While some of that may reflect cyclical consumer behavior amid all-time high coffee prices—both as a global commodity and for U.S. retail prices—Starbucks has also suffered from poor optics. Multi-year protests by labor union supporters as well as a boycott campaign rooted in the Israel-Gaza conflict has bled into 2025, significantly impacting the company’s sales.

Get Starbucks alerts:

Last week, the coffee chain announced plans to close stores and conduct another round of layoffs. But as Starbucks debuts a new strategic plan to bolster sales, there are fundamental issues that may go unanswered. Meanwhile, one competitor is making waves and providing an alternative for investors looking to harness the upside potential of a company that went public in 2021 and is now the fastest-growing retail coffee chain. 

Starbucks’ Struggles Aren’t Isolated to Last Quarter
Despite a small revenue increase in Q3, Starbucks saw comparable store sales as well as transactions decline significantly throughout the first second and third quarters of its fiscal year. In response, chairman and CEO Brian Niccol announced in late September a restructuring plan billed as “Back to Starbucks.” 

As part of that new strategy, which entails a $1 billion restructuring, 900 non-retail employees will be laid off. This marks the second round of layoffs with Niccol at the helm, following 1,100 workers being let go earlier in 2025. Other notable features of the “Back to Starbucks” plan include the return of the condiment bar, a marketing shift away from highlighting discounts, and efforts to increase pricing transparency—for example, by removing upcharges for non-dairy milk. 

However welcome those measures may be, bringing back condiment bars doesn’t appear to be the solution to more systemic issues that the company faces. In April, a lawsuit was filed against Starbucks by Brazilian workers who alleged forced labor in the company’s coffee supply chain. One month later, hundreds of its baristas across the United States staged walkouts to protest a new dress code policy, and in September, the union representing its eligible workers claimed that 59 of the locations Starbucks has decided to close were unionized stores. 

The restructuring plan will come at a sizable cost, too. According to a Form 8-K filing Starbucks made with the SEC, the company is expected to have to shell out $150 million in employee separation costs (e.g., severance pay, unemployment taxes and administrative tasks such as exit interviews and payroll updates) and another $850 million in payments related to its store closures (e.g., breaking leases due to store closures before the end of contractual terms). 

While the company remains a decent option for income investors—its dividend currently yields 2.81%, or $2.44 per share annually—its dividend payout ratio of 105.17% is an enormous red flag and seemingly unsustainable.  

One Competitor Undergoing Rapid Expansion
While the impacts of the “Back to Starbucks” strategic plan won’t materialize for some time, it is a clear indication—underscored by downsizing its location and staffing footprints—that the company is not in growth mode. 

But for investors who are dialed into America’s insatiable appetite for coffee, it isn’t all bad news. Other retailers operating in the consumer discretionary sector are providing better upside potential, stronger earnings, and better growth prospects.

Dutch Bros Today

$50.52 -1.81 (-3.46%)

As of 10/3/2025 03:59 PM Eastern

This is a fair market value price provided by Polygon.io. Learn more.

52-Week Range$30.49▼

$86.88P/E Ratio107.49

Price Target$79.88

Dutch Bros NYSE: BROS continues to outperform Starbucks in share appreciation, earnings, and revenue growth. The company, which went public in September 2021, is favored among Wall Street, with higher institutional ownership at nearly 86% versus Starbucks’ 72%. 

Last quarter, Dutch Bros beat on earnings by 44.44% while seeing its quarterly revenue grow 28% year-over-year. The company is expected to grow its earnings 38.60% next year. Analysts are in agreement that Dutch Bros’ performance over the next year will outperform that of Starbucks, with an average 12-month price target of $79.88 representing nearly 52% upside potential from today’s share price.

Since the stock ran up in the wake of its blowout Q2 earnings call in August, BROS has retraced nearly 30%. But it appears to have found support just above its YTD low set on April 4. With a current Relative Strength Index (RSI) reading of 29.97, the stock is considered oversold, which could foretell the start of a dramatic near-term price reversal. The last time Dutch Bros’ RSI was in oversold territory on July 24, it preceded a 27% gain through Aug. 28. 

Should You Invest $1,000 in Starbucks Right Now?Before you consider Starbucks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Starbucks wasn't on the list.

While Starbucks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Lighter, a decentralized perpetuals trading protocol, has officially gone live with its Ethereum Layer 2 mainnet after eight months of intensive beta testing. Positioned as a direct competitor to Hyperliquid and other decentralized derivatives platforms, Lighter is seeking to redefine the way perpetual trading functions in the onchain economy.

The leading cryptocurrency's previous all-time high was set on Aug. 14 around $124,533, according to Coinbase.

The ultimate battlefield: 1inch cofounder Sergej Kunz is coming for centralized exchanges Christina Comben · 24 seconds ago · 4 min read

1inch co-founder Sergej Kunz is transforming DeFi by uniting fragmented liquidity, pioneering seamless cross-chain swaps, and laying the groundwork for a UX to render centralized exchanges obsolete.

Oct. 5, 2025 at 2:00 pm UTC

4 min read

Updated: Oct. 4, 2025 at 11:59 am UTC

Cover art/illustration via CryptoSlate. Image includes combined content which may include AI-generated content.

Welcome to Slate Sunday, CryptoSlate’s weekly feature showcasing in-depth interviews, expert analysis, and thought-provoking op-eds that go beyond the headlines to explore the ideas and voices shaping the future of crypto.

Ask 1inch co-founder Sergej Kunz about where DeFi is headed, and you’ll get more than just your standard answer about financial inclusion or a hedge against fiat collapse.

Kunz isn’t one to mince his words, and he dives into the future of the sector like a hunter tracking his prey; focused, relentless, and entirely undaunted. For Kunz, DeFi’s future is seamless and, ultimately, peer-to-peer, delivering a UX so smooth it makes centralized exchanges obsolete.

As the leading DEX aggregator and DeFi ecosystem, complete with a sleek new rebrand, 1inch recently integrated with Solana and launched native, decentralized swaps spanning over 12 EVM networks. Smiling broadly, Kunz lays it out:

“We recognized that we need to grow; the whole DeFi space is not just on Ethereum anymore.”

It’s a sign of the times. From its early days in 2019, 1inch was strictly an Ethereum story, riding the first wave of DeFi innovation. Kunz recalls:

“We started on Ethereum. It was only Ethereum. And we added more EVM-compatible chains like Binance Smart Chain, Polygon, all the layers.”

Now, 14 chains later (with Solana joining the pack in April of this year), one thing is clear: DeFi’s borders get blurrier by the week, and his vision of seamless interoperability between ecosystems is no longer a distant dream.

“We started to combine the DeFi space, all the chains together, and now growing to non-EVM compatible chains. We will also add Bitcoin and all other blockchains that we can integrate for the cross-chain swaps, so we can unite all the liquidity in one single place.”

If it sounds ambitious, that’s probably because it is. Kunz isn’t the type of person to settle for second best. And why stick with fragmented liquidity when one platform can unite it all?

1inch: trustless swaps and seamless executionKunz’s relentless cross-chain focus comes paired with a laser eye on both security and price. He’s emphatic about user autonomy and respecting the core pillars of decentralized finance (like removing the middleman).

“Our value proposition is non-custodial swaps, which means no one needs to trust anyone. And the second value proposition is the best execution on the most liquidity that is available out there.”

But uniting liquidity means more than just technical gymnastics. There’s a longer-term goal, and it’s about rendering centralized exchanges to a footnote in crypto history. He affirms:

“Theoretically, no one needs centralized exchanges by using 1inch.”

Kunz insists that the magic of 1inch lies in user experience, unifying the UX across multiple ecosystems and chains.

But how close is DeFi to that mythical single-click, chain-agnostic flow that web2 users want?

“We are almost there,” he says. “Right now, when you do a cross-chain swap, you just connect your wallet, you click, and you confirm. You don’t do any transaction by yourself.”

Intent-based protocols, or ‘solving your own problem’Behind the scenes, it’s taken innovation. The 1inch protocol was invented in 2022 as a means of making DeFi fairer and combating “sandwich attacks,” the particular brand of front-running that haunts liquidity providers and traders alike. He explains:

“We call it an intent-based protocol for swaps.”

That phrase, ‘intent-based protocol’, has been cropping up everywhere lately. Uniswap X has written about it, and, in fact, Kunz points out that Uniswap X is based on 1inch’s idea; it is even cited in their whitepaper.

“We can create a protocol that sells user orders to market makers, arbitrage traders, and let the market makers compete between each other.”

Kunz compares 1inch’s approach to traditional exchanges like the Nasdaq, in that people create orders and market makers fill them. What’s different here is giving the order directly to an open, competitive ecosystem of professional traders who come first, settle first, and also partially fill. The numbers prove the point:

“We have use cases where someone exchanged 12 million USDT to Ethereum and got $135,000 more. If they did it by themselves using a DEX directly, they would get less.”

He recounts his own experience with sandwich attacks, saying:

“I was sandwiched… front-run by a malicious exchange. And I recognized, okay, we need to fix this.”

The intent-based protocol was, therefore, born from necessity, he says with a grin:

“I solved my own problem. No one can sandwich you or manipulate the liquidity.”

From DeFi to the broader crypto spaceThe conversation turns to stablecoins and the user experience gaps between chains. I point out that, despite the improvements, DeFi is still fiendishly tricky for normies to navigate, switching between networks and setting up wallets. He shrugs and says the ultimate goal is for users to never need to worry about networks or bridges.

“It should be that users should not care about the chain… they should just care what they have in USDC.”

As the roadmap stretches forward, growth is the only certainty for Kunz.

“We unite DeFi liquidity… and then we go to the crypto space. We integrate Bitcoin. You can buy any sh*t coin, memecoin, whatever coin. You can buy real Bitcoin, you get it in your wallet, and you can also sell Bitcoin. Same for Litecoin, same for Ripple.”

1inch’s vision is clear: to grow from the “small DeFi space” to the broader web3 world, and eventually touch traditional finance as well. He elaborates:

“A lot of companies right now, all the banks, do tokenization of real-world assets, but there’s no secondary trading place where you can trade them in one place. You need to go to every issuer, maybe to a bank, to a single bank, for example, to buy tokenized wine. You cannot just offer it like that. You need proper regulation for that… Our plan is to offer our protocols and our software service APIs for institutions to exchange such assets in a highly safe, non-custodial manner.”

The showdown with centralized exchangesAnd what’s on the immediate horizon for 1inch? Kunz explains that the one-to-three-year plan is to “push forward,” integrate more chains, go more cross-chain, and provide a more seamless experience. Finally, he says with a glint in his eye:

“To battle, test, and compete with centralized exchanges.”

Did I mention that Kunz was ambitious?

While most at the helm of CEXs envision a world where DeFi and CeFi coexist, the juggernauts of decentralized finance don’t easily forget being front-run.

And, with centralized exchange spot volume dropping nearly 28% in Q2 2025, CEXs should be sleeping with one eye open. DeFi is coming for their lunch.

Mentioned in this article

Sun, 5/10/2025 - 13:23

XRP enters new stage of adoption, and it's about privacy, Ripple CEO confirms

Cover image via U.Today

Ripple CEO confirmed the next stage for XRP’s institutional adoption, and it is privacy. That’s what prominent XRP Ledger contributor, known online as Vet, shared in a recent X post with a photo of him speaking directly to Garlinghouse, Ripple’s chief executive.

Garlinghouse’s answer highlights what many in the XRP Ledger community already see as the final gap in the ecosystem. The network has introduced decentralized identifiers (DID), on-chain credentials and permissioned domains to bring compliance into the picture.

It now supports multipurpose tokens (MPTs) for efficient tokenization, along with a native DEX that combines AMM liquidity with an order book.

HOT Stories

I asked Brad here what's the path to get more institutional adoption on the XRP Ledger, so that institutions are comfortable with sharing tx hashes with us.

>He said privacy.

Fast forward it all makes sense and fits nicely together.

We passed many compliance amendments like… pic.twitter.com/OfTSBvATEH

— Vet 🏴‍☠️ (@Vet_X0) October 5, 2025 What remains, according to both developers and Ripple leadership, is a privacy layer. That includes lending and borrowing functions under proposal XLS-66, where institutions could use tokenized real-world assets as collateral, while zero-knowledge proofs (ZKPs) keep balances and transfers confidential.

Privacy here is not about secrecy from regulators, but about allowing institutions to protect sensitive data from competitors while still proving compliance on-chain.

Trillions for private XRPRipple’s Senior Director of Engineering Ayo Akinyele recently pointed out that trillions in institutional assets are likely to move on-chain in the coming decade, and privacy will be central to making that happen. His team is already working on confidential MPTs, scheduled for launch in Q1, 2026, which would allow private collateral management at scale.

With smart escrows under XLS-100 and smart contracts under XLS-101 tying these functions together, privacy is the bridge Akinyele expects will carry XRP Ledger into its institutional era.

Related articles

MetaMask plans to launch a major on-chain rewards program within the next few weeks, distributing over $30 million in LINEA (LINEA) tokens during Season 1.

Summary

The move signals MetaMask’s push to deepen user engagement ahead of a potential token launch, as major Web3 platforms race to reward loyal users and solidify community ecosystems.
By combining on-chain incentives with a forthcoming token narrative, MetaMask is positioning itself at the center of the next wave of decentralized user growth.

One of the largest on-chain rewards programs ever
The Consensys-owned Web3 wallet described the initiative as “one of the largest on-chain rewards programs ever built,” designed to regularly give back to its community.

gm foxes 🦊

Yes, a rewards program is on the way. 👀

Any of the details you've previously seen/heard are not indicative of what is to actually launch. Let's talk a little bit about what the actual MetaMask Rewards program WILL be.

This program will yield referral rewards, mUSD…

— MetaMask.eth 🦊 (@MetaMask) October 4, 2025

The program will feature referral bonuses, mUSD stablecoin incentives, partner rewards, and token access. Long-time MetaMask users will receive special perks, tying into the future MetaMask token teased by Consensys CEO Joseph Lubin in September.

MetaMask clarified that earlier leaks about the program’s details did not reflect its actual launch parameters. The platform is tailoring incentives to different user groups, with a focus on veteran supporters.

LINEA tokens will serve as the main reward for Season 1. Linea, an Ethereum Layer 2 network also incubated by Consensys, launched its native token in September through a 9.4 billion token airdrop.

The program also integrates MetaMask’s new mUSD stablecoin, issued by Stripe-owned Bridge, which launched on Ethereum and Linea but does not offer yield-bearing features.

Questions remain about geographic eligibility and anti-Sybil measures to prevent abuse through multiple accounts.

The announcement drew mixed reactions on X. Crypto streamer Gainzy responded sarcastically, writing, “[T]his will go over well and no one will be disgusted and insult you.”

The skepticism highlights broader concerns that token and rewards programs often favor insiders over regular community members.

MetaMask’s insistence that the initiative isn’t a “farming play” appears aimed at easing those fears. The link to a potential MASK token has also fueled speculation about how participation might influence future token allocations.

Walmart-backed fintech platform OnePay is preparing to add cryptocurrency trading to its mobile banking app, a move that positions the retail giant's financial arm firmly in the middle of the growing digital asset economy. The integration, set to roll out later this year, will allow users to buy, sell, and custody Bitcoin (BTC) and Ethereum (ETH) directly within the app.

With Bitcoin (BTC) hitting a new all-time high above $125,000, an analyst has noted that the asset is likely to see more momentum, but investors should also expect a correction.

According to analysis by CrediBULL Crypto, the current rally marks the beginning of a broader move toward $150,000 and beyond, though a retracement to lower levels would be both natural and healthy for the market.

In an X post on October 5, the analyst highlighted that Bitcoin is in the early stages of a new five-wave impulse pattern. 

Bitcoin price analysis chart. Source: CrediBULL Crypto
Following the initial breakout, a corrective wave could drive prices back toward a key demand zone between $108,000 and $118,000. 

This area is identified as a potential accumulation zone where traders who previously shorted the market may be forced to cover, adding strong support.

Additionally, the analyst noted that short-sellers between $118,000 and $108,000 are now trapped after the breakout, making this zone a likely area of significant buying pressure if retested. 

Now, any dip into this range would be a “blessing,” while avoiding a pullback could see Bitcoin surge past $150,000. 

Whales showing more interest in Bitcoin
On-chain data further supports the possibility of continued momentum as large investors show growing confidence in the asset. 

To this end, data shared by Ali Martinez indicates that Bitcoin’s accumulation trend score has climbed to 0.74, reflecting steady balance growth among both new and existing wallets. 

The metric, tracked by Glassnode, signals aggressive accumulation when elevated, pointing to rising demand from larger entities. 

Bitcoin price analysis
As of press time, Bitcoin was trading at $122,727, up 0.3% in the last 24 hours and 12% higher on the week.

Bitcoin seven-day price chart. Source: Finbold
From a technical perspective, Bitcoin remains well above its 50-day and 200-day simple moving averages, confirming a sustained upward trajectory with no immediate signs of reversal.

Meanwhile, the 14-day RSI sits at 68.02, in bullish territory (above 50 but just under the overbought threshold of 70), suggesting solid momentum without exhaustion.

Featured image via Shutterstock

Key points:

Bitcoin begins a retracement after hitting new all-time highs above $125,000.

Sunday trading produces BTC price volatility as traders eye potential bounce levels.

Institutions are on the radar as Bitcoin “debasement trade” talk heats up.

Bitcoin (BTC) experienced fresh volatility as it approached Sunday’s weekly close, following a BTC price correction from all-time highs.

BTC/USD one-hour chart. Source: Cointelegraph/TradingViewAnalysis: 4% BTC price drop possibleData from Cointelegraph Markets Pro and TradingView showed BTC/USD dropping back below $123,000.

The pair hit new record highs above $125,000 earlier in the day, fueled by derivatives markets in unusual weekend trading.

Commenting on the latest price action, popular trader Skew warned that the entire move to the upside may be “bait” for longs.

“Passive shorts compounding here,” he observed in a post on X, referring to traders attempting to short price at the highs.

“Shorts opening here on the consensus that the weekend pump is bait.”BTC liquidation heatmap (screenshot). Source: CoinGlassData from CoinGlass showed liquidity on exchange order books being taken either side of price.

Crypto market participants tend to view weekend moves, both up and down, as unreliable indicators of where the price will ultimately head next, due to a lack of market liquidity.

Considering where the retracement may bottom, trader CrypNuevo eyed the 50-period exponential moving average (EMA) on four-hour timeframes, currently just above $118,000.

“For the week ahead, I think we could see a 4h50EMA retest - it’s overextended and you can see the retests in previous similar Price Action,” he wrote in an X thread. 

“After that, we should see a new move up higher. Therefore, I'm still favoring longs over shorts from the 4h50EMA.”BTC/USDT four-hour chart with 50EMA. Source: CrypNuevo/XPopular trader and analyst Rekt Capital also used historical comparisons to chart future BTC price performance. $124,000, he argued, may take time to break definitively.

“There's should be no surprise that Bitcoin has rejected from ~$124k on the first time of asking in this uptrend. After all, the last time Bitcoin rejected from $124k, the rejection preceded a -13% pullback,” he reasoned.

“Bitcoin needs to prove this $124k resistance is a weakening point of rejection. And any shallower dip or pullback from here would do just that.”BTC/USD one-week chart. Source: Rekt Capital/XRekt Capital added that BTC/USD could drop as much as 4% and still preserve the weekly uptrend.

Bitcoin “debasement trade” gathers steamBullish takes, meanwhile, focused on the presence of institutional interest.

Caleb Franzen, creator of financial research resource Cubic Analytics, said that the absence of BTC price pullbacks so far demonstrated sizable demand.

“When I see short-term price action like this, with minimal pullbacks and large spikes to the upside followed by sustained bids, I see institutions,” part of various X updates on the day read.

Mainstream finance commentators referenced Bitcoin’s position in the “debasement trade,” referring to investors’ desire to hedge against the declining value of fiat currencies.

Digital #Gold - aka #Bitcoin – is following its analogue counterpart, hitting a new record high >$125k – a milestone in the ongoing debasement trade, as investors seek protection from currency devaluation. pic.twitter.com/KHjeet5EW8

— Holger Zschaepitz (@Schuldensuehner) October 5, 2025
Cointelegraph reported on the trend, the name of which was coined by analysts at JPMorgan, at the start of the year.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.

Journalist

Posted: October 5, 2025

Key Takeaways
Why is DOGE attracting renewed attention?
Despite a $20 billion market pullback in September, DOGE closed with a 9% ROI, with top 1% addresses holding 96.45%, signaling strong smart money backing.

What makes Dogecoin’s Q4 setup bullish?
Whales injected 30 million DOGE, NUPL shows a solid support at $0.23–$0.25, and HODLers are back in profit, setting the stage for a potential $0.30 breakout and renewed ETF hype.

Dogecoin [DOGE] is flashing signs that the whole “ETF hype” might actually have legs. Even after the memecoin sector wiped out $20 billion in September’s second half, DOGE still pulled off a clean 9% move up.

In fact, on a 30-day basis, it’s actually leading the pack with a solid 21% rally, marking a sharp contrast to Q1 and Q2, when it dumped over 50% from its election-fueled run toward $0.40.

This Q3 resilience (clocking a 41%+ ROI) signals a clear shift in sentiment. Traders seem to be rotating back into DOGE’s classic “high-risk, high-reward” setup as risk appetite creeps back into the market.

Source: Coinglass

Reinforcing the move, top 1% addresses now hold 96.45% of DOGE, hitting a fresh all-time high. Derivatives aren’t screaming “overheated”, which tells us spot demand is still solid with leverage under control.

In fact, as a prominent analyst tracked, whales have kicked off Q4 with fresh accumulation, recently injecting 30 million coins, aligning with DOGE’s 13% monthly run, which is already outperforming its peers.

All in all, smart money’s leaning into DOGE. Even in a risk-off phase, fresh capital flowed in, while speculative positions stayed in check, setting up a perfect insitutional setup for Dogecoin’s ETF narrative.

DOGE’s on-chain metrics translate to stronger gains
Dogecoin’s robust on-chain activity is translating into tangible returns.

Q3 produced DOGE’s most bullish run since the election rally, delivering a 41% ROI, though this still trails the 47% losses from Q1. In short, early-year HODLers remain underwater.

Looking at the NRPL, DOGE dropping below $0.23 flipped the metric into red, showing traders lost conviction and chased breakeven to prevent further losses, establishing this level as a support case for DOGE’s Q4 run.

Source: Glassnode

In short, DOGE holding support keeps FOMO alive.

At press time, it’s $0.26, up 5% intraday, with $0.24–$0.25 acting as a third higher low, synced with smart money stacking. Simply put, bulls are structuring a clean, whale-backed setup.

Against this backdrop, with HODLers back in profit and FOMO high, holding for bigger gains looks likely. Thus, a $0.30 breakout would only pump Dogecoin’s ETF narrative.

Ritika Gupta is a Financial Journalist and Geopolitical Analyst at AMBCrypto, specializing in the critical intersection of world politics, economic policy, and the cryptocurrency markets. Her analysis is informed by her distinguished background, which includes professional experience at major news network.
She holds a Bachelor's degree in Political Science and Psychology from Gargi College, University of Delhi. This academic training provides her with a sophisticated framework for dissecting complex issues such as international regulations, government fiscal policies, and the geopolitical forces that directly influence asset valuations.
At AMBCrypto, Ritika applies this expert lens to synthesize macroeconomic data and political developments, offering readers a deeper context for market movements. She excels at explaining not just what is happening in the market, but why it is happening. Her work is dedicated to providing strategic insights that empower readers to understand the complex relationship between global events and their digital assets.

The cryptocurrency ETF market in the United States is preparing for a seismic shift as REXShares and Osprey Funds jointly submitted applications for 21 new cryptocurrency exchange-traded funds (ETFs). This filing, one of the largest coordinated pushes to expand crypto investment options, includes major altcoins like Cardano (ADA), Avalanche (AVAX), and Polkadot (DOT), alongside a broad mix of established and emerging digital assets.